| P/E (FY) | — | Sales (TTM) | SEK 59.7M |
| Earnings (TTM) | -SEK 233.9M | ROE | — |
| Net Margin | −391.70% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 58.04% |
Alligator Bioscience AB is a research-based biotechnology company developing antibody-based pharmaceuticals for the treatment of cancer. Its clinical candidates include Mitazalimab, a CD40-targeting stimulatory antibody in Phase 3 testing for solid metastatic tumors including pancreatic cancer, along with ALG.APV-527, ATOR-1017, HLX22, and the preclinical ATOR-4066. The company also builds drug candidates using proprietary technology platforms such as ALLIGATOR-GOLD, ALLIGATOR-FAB, FIND, and RUBY, and has collaboration and out-licensing agreements with partners including Aptevo Therapeutics, Orion, BioArctic, and Henlius. Incorporated in 2000, Alligator Bioscience is headquartered in Lund, Sweden.
| Market Cap | $3.4M | Trading Days | 2293 |
| 52W High | 6.04 |
| 52W Low | 0.03 |
| % Off High | −99.28% |
| YTD | −87.03% | 1Y | −99.25% |
| 3Y | −99.87% | 5Y | −99.99% |
| Since incept. (ann.) | −66.51% |
| Ann. Volatility (1Y) | 180.93% | Ann. Volatility (3Y) | 285.01% |
| Sharpe (1Y) | −1.68 | Sharpe (3Y) | 0.02 |
| Max Drawdown (1Y) | −99.25% | Max Drawdown (3Y) | −99.96% |
| Beta (3Y, vs SPY) | 4.00 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ACUT | Accustem Sciences Inc. | $3.5M | — |
| ENSC | Ensysce Biosciences, Inc. | $3.7M | — |
| STRAP.CO | Strategic Partners A/S | $3.9M | — |
| JUNS | JUPITER NEUROSCIENCES, INC. | $4.0M | — |
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | $4.0M | — |
| NXGL | NEXGEL, INC. | $4.0M | — |
| REVB | REVELATION BIOSCIENCES, INC. | $4.1M | — |
| BIAF | bioAffinity Technologies, Inc. | $2.8M | — |
| CVSI | CV Sciences, Inc. | $4.1M | — |
| EPIS-B.ST | Episurf Medical AB | $2.8M | — |
| NICA.ST | Nanologica AB (publ) |
| $4.1M |
| — |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | $2.7M | — |
